Results from a study conducted at Georgia State University suggest that a "fight" between bacteria normally living in the intestines and the immune system, kicked off by another type of bacteria, may be linked to two types of chronic disease.
The study suggests that the "fight" continues after the instigator bacteria have been cleared by the body, according to Andrew Gewirtz, professor of biology at the GSU Center for Inflammation, Immunity and Infection. That fight can result in metabolic syndrome, an important factor in obesity, or inflammatory bowel disease (IBD).
The results were published in the journal Cell Host & Microbe.
"The implication at present is that it is very important to control the early environment," Gewirtz says. "We need to examine how this can be achieved perhaps via breastfeeding, a more diverse diet, probiotics are possibilities."
The study's results are important as instances of chronic diseases like metabolic syndrome and IBD are increasing rapidly among humans, he explained.
Metabolic syndrome involves risk factors, including obesity, which can lead to cardiovascular disease, diabetes and stroke. According to the American Heart Association, about 35 percent of adults are affected by this syndrome.
IBD, which includes Crohn's disease and ulcerative colitis, happens when the intestines become inflamed, leading to abdominal cramps and pain, diarrhea, weight loss and bleeding.
More than 600,000 Americans annually have some kind of inflammatory bowel disease, according to the American Academy of Family Physicians.
Bacteria normally live in the gut of humans, with the average human having about 4 pounds of bacteria living there.
"It is increasingly apparent that bacteria are playing a role in healthy development, and need to be properly managed by the mucosal immune system to avoid inflammatory diseases" Gewirtz says.
The study team included Gewirtz, Frederic Carvalho, Omry Koren, Julia Goodrich, Malin Johannson, Ilke Nalbantoglu, Jesse Aitken, Yueju Su, Benoit Chassing, William Walters, Antonio Gonzalez, Jose Clemente, Tyler Cullender, Nicolas Barnich, Arlette Darfeuille-Michaud, Matam Vijay-Kumar, Rob Knight and Ruth Ley.
Participating institutions included GSU's Center for Inflammation, Immunity and Infection and the Department of Biology; Clermont University of the Universite d'Auvergne in France; Insern; the Department of Microbiology of Cornell University; the Department of Medical Biochemistry of the University of Gothenberg in Sweden; and the Department of Pathology and Immunology of the Washington University School of Medicine in St. Louis, Mo.
Additional institutions involved included the Department of Cellular, Molecular and Developmental Biology, the Department of Computer Science and the Department of Chemistry and Biochemistry of the University of Colorado at Boulder; and the Howard Hughes Medical Institute.
The study, "Transient inability to manage Proteobacteria drives gut inflammation in TLR5-deficient mice," appears in the Aug. 16 print edition of the journal Cell Host & Microbe.
Â
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.